Ep127: Jeb Keiper on Computational Drug Discovery

Episode Summary

Executive Summary: Jeb Kuiper traces his path from blue-collar roots in Allentown to leading Nimbus Therapeutics, explaining how a physics-based, computational-first discovery model produced two major partnered assets and culminated in Takeda’s $4 billion upfront acquisition of Nimbus’s TIC2 inhibitor. The conversation emphasizes scientific rigor, organizational design, and why a lean biotech can outperform scale in early drug discovery.

Main Topics: Kuiper’s personal path into biotech (Priority: 5/5): He recounts growing up in Allentown, discovering chemistry through inspiring teachers, studying at MIT, then moving from lab science to consulting and business development before returning to biotech leadership. Nimbus’s computational-first discovery platform (Priority: 5/5): Nimbus was built to use high-performance computing, physics-based modeling, and cloud/GPU advances prospectively to design small molecules, rather than using software only retrospectively. Nimbus’s unconventional corporate structure (Priority: 4/5): The company used an LLC/topco structure with program-level subsidiaries to optimize partnering and acquisitions while keeping employees aligned through shared top-level equity. From ACC/NASH to TIC2: validating the model twice (Priority: 5/5): Nimbus first validated itself by partnering its ACC inhibitor in NASH to Gilead, then later advanced TIC2 through the clinic and ultimately sold it to Takeda after strong psoriasis results. TIC2 biology and competitive landscape (Priority: 5/5): Kuiper explains why selective TIC2 inhibition is compelling genetically for autoimmune disease, how it differs from broader JAK inhibition, and how Bristol-Myers Squibb’s competing asset clarified the class. Deal-making, antitrust, and value creation (Priority: 5/5): The Celgene/BMS merger created an antitrust and option dispute over TIC2, but Nimbus continued development, retained ownership after settlement, and ultimately monetized the asset at a major valuation. Nimbus’s next chapter (Priority: 4/5): After the Takeda deal, Nimbus intends to remain lean, keep its integrated R&D culture, and continue advancing a broader pipeline including oncology and additional clinical starts.

Key Arguments: A computational-first, physics-based approach can generate genuinely novel small molecules when paired with enough compute and disciplined medicinal chemistry. Nimbus’s subsidiary-based LLC structure is efficient for pharma partnering because buyers often want one program, not the entire company. Aligning all employees and investors at the topco level avoids perverse incentives and builds a true team culture across risky R&D programs. Target validation is strongest when a discovery group produces a drug that reaches patients, not just good preclinical data. Selective TIC2 inhibition is attractive because human loss-of-function genetics suggest efficacy in autoimmune disease with an apparently favorable safety profile. Continuing development during legal and corporate uncertainty was essential; pausing the program would have destroyed value and momentum. Small, expert R&D organizations can outperform large ones in biotech by staying focused and using leading-edge technology well.

Data Points: Takeda upfront payment for TIC2 asset: $4 billion - Nimbus sold its experimental TIC2 inhibitor to Takeda after positive Phase IIb psoriasis data. Potential milestones: $2 billion - Additional contingent value in the Takeda transaction. Nimbus ACC inhibitor deal with Gilead: $400 million upfront + $200 million more soon after - Nimbus’s first major partnership validated its discovery model. TIC2 psoriasis Phase IIb study size: 260 patients - Placebo-controlled trial supporting the asset’s value. Psoriatic arthritis study size: 260 patients - A second Phase IIb study started alongside psoriasis. Once-daily dosing: 24-hour half-life - Kuiper described TIC2 as an orally available small molecule with a favorable PK profile. Homozygous TIC2 loss-of-function frequency: ~1 in 600 Caucasians - Used to support the target’s human genetics and safety rationale. Nimbus employee count at Kuiper’s start: ~13 employees - He joined a small organization and later grew with it. Nimbus size later in the story: ~80 people - The company remained relatively lean despite advancing multiple programs. GSK oncology divestiture deal size: $25 billion - Large three-way asset deal involving GSK, Novartis, and consumer healthcare assets. TIC2 deal timing: Announced in December - Luke references the deal as one of the biggest biotech transactions of 2022.

Pivotal Quotes: "There are benefits to scale, but in R&D, I don't know that you see them." — Jeb Kuiper: Explaining why Nimbus chooses to remain relatively small and focused. "We are looking for people who really would want to be part of a community, would want to build a pipeline, more missionaries rather than mercenaries." — Jeb Kuiper: Describing Nimbus’s employee alignment philosophy and equity design. "Never doubt that a small group of people can change the world. In fact, it's the only thing that ever has." — Luke Timmerman: Closing reflection on Nimbus’s impact and the power of lean, high-performing teams.

Implications: The conversation suggests that disciplined science, smart company design, and patience can create enormous biotech value. For investors and founders, Nimbus is a case study in how lean teams and strong platform validation can outperform scale.